urea has been researched along with Parkinson Disease in 83 studies
pseudourea: clinical use; structure
isourea : A carboximidic acid that is the imidic acid tautomer of urea, H2NC(=NH)OH, and its hydrocarbyl derivatives.
Parkinson Disease: A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75)
| Excerpt | Relevance | Reference |
|---|---|---|
| "In a trial that was stopped early for efficacy, patients with dementia-related psychosis who had a response to pimavanserin had a lower risk of relapse with continuation of the drug than with discontinuation." | 9.41 | Trial of Pimavanserin in Dementia-Related Psychosis. ( Ballard, C; Cummings, JL; Devanand, DP; Erten-Lyons, D; Foff, EP; McEvoy, B; Soto-Martin, ME; Stankovic, S; Sultzer, DL; Tariot, PN; Weintraub, D; Youakim, JM, 2021) |
| "Evaluate pimavanserin treatment for depression in patients with PD." | 9.34 | An Open-Label, 8-Week Study of Safety and Efficacy of Pimavanserin Treatment in Adults with Parkinson's Disease and Depression. ( Abler, V; Aldred, JL; Alva, G; Cantillon, M; Coate, B; DeKarske, D; Jacobi, L; Norton, JC; Nunez, R, 2020) |
| "This study provides Class II evidence that in patients with Parkinson disease who are 65 or older and residing in Medicare-certified long-term care facilities, pimavanserin is associated with an increased risk of 30-day hospitalization and higher 90-, 180-, and 365-day mortality." | 8.02 | Risk of Hospitalization and Death Associated With Pimavanserin Use in Older Adults With Parkinson Disease. ( Alexander, GC; An, H; Hwang, YJ; Mehta, HB; Moore, TJ, 2021) |
| "Pimavanserin is a first-in-class selective serotonin 5-HT2A receptor inverse agonist approved for the treatment of Parkinson disease psychosis." | 7.91 | Can pimavanserin help patients with Parkinson disease psychosis? ( Canal, C; de la Cruz, J, 2019) |
| "Pimavanserin may prove beneficial in treating the hallucinations and delusions of DRP without worsening cognitive or motor function." | 6.82 | Dementia-related psychosis and the potential role for pimavanserin. ( Cummings, JL; Devanand, DP; Stahl, SM, 2022) |
| "Psychosis is common across dementia types with a prevalence of 20% to 70%." | 6.58 | Pimavanserin: Potential Treatment For Dementia-Related Psychosis. ( Ballard, C; Cummings, J; Foff, E; Norton, J; Owen, R; Stankovic, S; Tariot, P; Youakim, J, 2018) |
| " The compound was also well-tolerated in a first-in-human oral dosing study in healthy and older volunteers with a favorable, dose-dependent pharmacokinetic profile." | 5.72 | The Compound ATH434 Prevents Alpha-Synuclein Toxicity in a Murine Model of Multiple System Atrophy. ( Adlard, PA; Barnham, KJ; Billings, JL; Cherny, RA; Finkelstein, DI; Saleh, E; Shukla, JJ; Stefanova, N, 2022) |
| "In a trial that was stopped early for efficacy, patients with dementia-related psychosis who had a response to pimavanserin had a lower risk of relapse with continuation of the drug than with discontinuation." | 5.41 | Trial of Pimavanserin in Dementia-Related Psychosis. ( Ballard, C; Cummings, JL; Devanand, DP; Erten-Lyons, D; Foff, EP; McEvoy, B; Soto-Martin, ME; Stankovic, S; Sultzer, DL; Tariot, PN; Weintraub, D; Youakim, JM, 2021) |
| "Evaluate pimavanserin treatment for depression in patients with PD." | 5.34 | An Open-Label, 8-Week Study of Safety and Efficacy of Pimavanserin Treatment in Adults with Parkinson's Disease and Depression. ( Abler, V; Aldred, JL; Alva, G; Cantillon, M; Coate, B; DeKarske, D; Jacobi, L; Norton, JC; Nunez, R, 2020) |
| " Participants were receiving 40 mg pimavanserin daily in addition to concurrent antipsychotics and Parkinson disease medications." | 5.20 | Impact of Current Antipsychotic Medications on Comparative Mortality and Adverse Events in People With Parkinson Disease Psychosis. ( Ballard, C; Burn, DJ; Coate, B; Corbett, A; Isaacson, S; Mills, R; Pahwa, R; Rascol, O; Williams, H, 2015) |
| "Pimavanserin was approved in April 2016 for the treatment of delusions and hallucinations of PDP." | 4.95 | Pimavanserin: A Novel Antipsychotic for Parkinson's Disease Psychosis. ( Bozymski, KM; Crouse, EL; Gatesman, TL; Lowe, DK; Pasternak, KM, 2017) |
| " Pimavanserin is the first FDA approved drug for the treatment of hallucinations and delusions associated with PDP." | 4.95 | Pimavanserin, a novel antipsychotic for management of Parkinson's disease psychosis. ( Kianirad, Y; Simuni, T, 2017) |
| "Pimavanserin 34 mg/d was effective in treating hallucinations and delusions associated with Parkinson's disease." | 4.95 | The US Food and Drug Administration's Perspective on the New Antipsychotic Pimavanserin. ( Andreason, P; Atrakchi, A; Avila, AM; Farchione, T; Mathis, MV; Muoio, BM; Temple, RJ, 2017) |
| "Pimavanserin (Nuplazid™) is a selective and potent serotonin 2A (5-HT2A) receptor inverse agonist and antagonist developed by ACADIA Pharmaceuticals that has been approved in the US as a treatment for patients with hallucinations and delusions associated with Parkinson's disease psychosis." | 4.93 | Pimavanserin: First Global Approval. ( Markham, A, 2016) |
| " This review provides an overview of 5-HT receptor pharmacology and discusses two recent 5-HT receptor subtype-selective drugs, lorcaserin and pimavanserin, which target the 5HT2C and 5HT2A receptors and provide new treatments for obesity and Parkinson's disease psychosis, respectively." | 4.89 | Lorcaserin and pimavanserin: emerging selectivity of serotonin receptor subtype-targeted drugs. ( Meltzer, HY; Roth, BL, 2013) |
| "Pimavanserin tartrate is the first 5-HT(2A) inverse agonist to enter clinical trials as a treatment for L-dopa-induced psychosis in Parkinson's disease and for augmentation of low-dose risperidone treatment in schizophrenia." | 4.84 | Pimavanserin tartrate: a 5-HT2A inverse agonist with potential for treating various neuropsychiatric disorders. ( Abbas, A; Roth, BL, 2008) |
| " Mortality analyses were adjusted for age, sex, levodopa equivalent daily dose (LEDD), and dementia." | 4.31 | Assessing the risks of treatment in Parkinson disease psychosis: An in-depth analysis. ( Alakkas, A; Liu, L; Longardner, K; Nahab, FB; Wright, BA; Xu, R; You, H, 2023) |
| "This study provides Class II evidence that in patients with Parkinson disease who are 65 or older and residing in Medicare-certified long-term care facilities, pimavanserin is associated with an increased risk of 30-day hospitalization and higher 90-, 180-, and 365-day mortality." | 4.02 | Risk of Hospitalization and Death Associated With Pimavanserin Use in Older Adults With Parkinson Disease. ( Alexander, GC; An, H; Hwang, YJ; Mehta, HB; Moore, TJ, 2021) |
| "Pimavanserin is a first-in-class selective serotonin 5-HT2A receptor inverse agonist approved for the treatment of Parkinson disease psychosis." | 3.91 | Can pimavanserin help patients with Parkinson disease psychosis? ( Canal, C; de la Cruz, J, 2019) |
| "Dementia due to Parkinson's disease and Alzheimer's disease are associated with behavioural and psychological symptoms, including psychosis." | 3.01 | Unmet needs in the diagnosis and treatment of Parkinson's disease psychosis and dementia-related psychosis. ( Isaacson, SH; Pagan, F; Pahwa, R; Sabbagh, M; Small, GW; Torres-Yaghi, Y, 2023) |
| "Pimavanserin has a unique mechanism of action." | 3.01 | A New Hope in Alzheimer's Disease Psychosis: Pimavanserin. ( Akın, M; Kurhan, F, 2023) |
| "PD psychosis is often associated with cognitive impairment, including dementia, and involves dopaminergic, serotonergic, and cholinergic mechanisms." | 2.87 | Pimavanserin for Parkinson's Disease psychosis: Effects stratified by baseline cognition and use of cognitive-enhancing medications. ( Andersson, C; Ballard, C; Coate, B; Espay, AJ; Factor, SA; Fredericks, D; Friedman, JH; Guskey, MT; Lang, AE; Larsen, NJ; Norton, JC; Vizcarra, JA; Weintraub, D, 2018) |
| "The terms "Parkinson's disease psychosis", "Parkinson psychosis," "neurodegenerative psychosis", and "dopamine psychosis" were among the keywords used in the search." | 2.82 | Psychosis in Parkinson's Disease: Looking Beyond Dopaminergic Treatments. ( Bautista-Sandoval, MJ; Bermúdez, V; Chacín, M; Chávez-Castillo, M; Cudris-Torres, L; Duran, P; Medina-Ortiz, O; Ortega, Á; Palmar, J; Riaño-Garzón, M; Rojas, M; Salazar, J, 2022) |
| "Pimavanserin may prove beneficial in treating the hallucinations and delusions of DRP without worsening cognitive or motor function." | 2.82 | Dementia-related psychosis and the potential role for pimavanserin. ( Cummings, JL; Devanand, DP; Stahl, SM, 2022) |
| "Pimavanserin may benefit patients with Parkinson's disease psychosis for whom few other treatment options exist." | 2.79 | Pimavanserin for patients with Parkinson's disease psychosis: a randomised, placebo-controlled phase 3 trial. ( Ballard, C; Chi-Burris, K; Corbett, A; Cummings, J; Dhall, R; Isaacson, S; Mills, R; Williams, H, 2014) |
| "There is a considerable overlap between Parkinson's Disease Dementia (PDD) and Dementia with Lewy Bodies (DLB)." | 2.66 | Treatment of psychosis in Parkinson's disease and dementia with Lewy Bodies: A review. ( Bronstein, JM; Kyle, K, 2020) |
| "Two cases of Parkinson's disease with an unusual delusional misidentification, intermetamorphosis, are presented, along with their improvement with pimavanserin, a novel atypical antipsychotic medication." | 2.58 | Delusional misidentification in Parkinson's disease: report of two cases and a review. ( Hermanowicz, N, 2018) |
| "We discuss features of Parkinson's disease psychosis (PDP) including symptomology and pathophysiology." | 2.58 | Treating Hallucinations and Delusions Associated With Parkinson's Disease Psychosis. ( Ondo, WG; Panchal, SC, 2018) |
| "Psychosis is a common problem for people treated for Parkinson's disease." | 2.58 | Pharmacological interventions for psychosis in Parkinson's disease patients. ( Friedman, JH, 2018) |
| "Psychosis is common across dementia types with a prevalence of 20% to 70%." | 2.58 | Pimavanserin: Potential Treatment For Dementia-Related Psychosis. ( Ballard, C; Cummings, J; Foff, E; Norton, J; Owen, R; Stankovic, S; Tariot, P; Youakim, J, 2018) |
| "Patients with Parkinson's disease psychosis (PDP) are often treated with an atypical antipsychotic, especially quetiapine or clozapine, but side effects, lack of sufficient efficacy, or both may motivate a switch to pimavanserin, the first medication approved for management of PDP." | 2.58 | Guidance for switching from off-label antipsychotics to pimavanserin for Parkinson's disease psychosis: an expert consensus. ( Adler, CH; Alva, G; Black, KJ; Cooney, JW; Isaacson, S; Kremens, D; Menza, MA; Meyer, JM; Morrissette, DA; Nasrallah, H; Pahwa, R; Patkar, AA; Simuni, T; Stacy, M; Stahl, SM, 2018) |
| "Psychosis is highly prevalent in PD patients and is associated with poor prognosis." | 2.53 | Pimavanserin for the treatment of Parkinson's disease psychosis. ( Chendo, I; Ferreira, JJ, 2016) |
| "Pimavanserin (ACP-103) is a selective inverse agonist of the 5-hydroxytryptamine 2A (5-HT2A) receptor intended to treat patients with Parkinson's disease psychosis (PDP)." | 2.52 | Pimavanserin. ( Anderson, KC; Cox, A; Hunter, NS, 2015) |
| "Pimavanserin displays nanomolar potency as a 5-HT2A receptor inverse agonist, selectivity for 5-HT2A over 5-HT2C receptors, and no meaningful activity at any other G-protein coupled receptor." | 2.50 | On the discovery and development of pimavanserin: a novel drug candidate for Parkinson's psychosis. ( Burstein, ES; Hacksell, U; McFarland, K; Mills, RG; Williams, H, 2014) |
| "Dementia associated with Parkinson's disease (PDD) is a common problem and one that is associated with significant morbidity and mortality." | 2.46 | Parkinson's disease dementia. ( Burn, DJ; Docherty, MJ, 2010) |
| " The compound was also well-tolerated in a first-in-human oral dosing study in healthy and older volunteers with a favorable, dose-dependent pharmacokinetic profile." | 1.72 | The Compound ATH434 Prevents Alpha-Synuclein Toxicity in a Murine Model of Multiple System Atrophy. ( Adlard, PA; Barnham, KJ; Billings, JL; Cherny, RA; Finkelstein, DI; Saleh, E; Shukla, JJ; Stefanova, N, 2022) |
| " Safety was evaluated from adverse events (AEs), clinical laboratory results, motor symptoms, electrocardiograms (ECG), and mortality." | 1.56 | Long-term evaluation of open-label pimavanserin safety and tolerability in Parkinson's disease psychosis. ( Abler, V; Azulay, JP; Ballard, CG; Demos, G; Fernandez, HH; Ferreira, JJ; Ilic, TV; Isaacson, S; Kreitzman, DL; Liu, IY; Norton, JC; Stankovic, S, 2020) |
| "Psychosis is common among patients with Parkinson's disease (PD) and dementia with Lewy bodies (DLB)." | 1.51 | Pimavanserin versus quetiapine for the treatment of psychosis in Parkinson's disease and dementia with Lewy bodies. ( Dahodwala, N; Horn, S; Richardson, H; Weintraub, D; Xie, SX, 2019) |
| "Pimavanserin is a newly approved treatment for Parkinson's disease psychosis, but real-world experience with pimavanserin has been limited by small sample sizes and limited assessment of longitudinal outcomes." | 1.51 | Pimavanserin for Psychosis in Parkinson's Disease-Related Disorders: A Retrospective Chart Review. ( Claassen, DO; Darby, RR; Farooque, A; Sellers, J, 2019) |
| "Psychotic disorders in Parkinson's disease (PDPD) are common and significantly influence the quality of life and disability level." | 1.43 | [Modern approaches to treatment of psychosis in Parkinson's disease]. ( Cozac, VV, 2016) |
| "Pimavanserin is an inverse agonist at the 5HT2A receptor, with a lower binding affinity at the serotonin-2C receptor and sigma 1 receptor, but no significant binding to dopamine or other receptors." | 1.43 | Pimavanserin: An Inverse Agonist Antipsychotic Drug. ( Howland, RH, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (3.61) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (2.41) | 29.6817 |
| 2010's | 55 (66.27) | 24.3611 |
| 2020's | 23 (27.71) | 2.80 |
| Authors | Studies |
|---|---|
| Finkelstein, DI | 1 |
| Shukla, JJ | 1 |
| Cherny, RA | 1 |
| Billings, JL | 1 |
| Saleh, E | 1 |
| Stefanova, N | 1 |
| Barnham, KJ | 1 |
| Adlard, PA | 1 |
| Subbiah, P | 1 |
| Doshi, D | 1 |
| Turner, ME | 1 |
| Hwang, YJ | 2 |
| Alexander, GC | 2 |
| Moore, TJ | 2 |
| Mehta, HB | 2 |
| Ma, M | 1 |
| Yang, Y | 1 |
| Du, G | 1 |
| Dai, Y | 1 |
| Zhu, X | 1 |
| Wang, W | 1 |
| Xu, H | 1 |
| Zhang, J | 1 |
| Zheng, L | 1 |
| Zou, F | 1 |
| Yang, H | 1 |
| Liu, B | 1 |
| Liu, W | 1 |
| Ye, L | 1 |
| Zhang, R | 1 |
| Tian, J | 1 |
| Sabbagh, M | 1 |
| Small, GW | 1 |
| Isaacson, SH | 3 |
| Torres-Yaghi, Y | 1 |
| Pagan, F | 2 |
| Pahwa, R | 3 |
| Galamba, N | 1 |
| Mosholder, AD | 1 |
| Ma, Y | 1 |
| Akhtar, S | 1 |
| Podskalny, GD | 1 |
| Feng, Y | 1 |
| Lyu, H | 1 |
| Liao, J | 1 |
| Wei, Y | 1 |
| Wernecke, M | 1 |
| Leishear, K | 1 |
| Nelson, LM | 1 |
| MaCurdy, TE | 1 |
| Kelman, JA | 1 |
| Graham, DJ | 1 |
| Schneider, LS | 1 |
| Rojas, M | 1 |
| Chávez-Castillo, M | 1 |
| Duran, P | 1 |
| Ortega, Á | 1 |
| Bautista-Sandoval, MJ | 1 |
| Salazar, J | 1 |
| Riaño-Garzón, M | 1 |
| Chacín, M | 1 |
| Medina-Ortiz, O | 1 |
| Palmar, J | 1 |
| Cudris-Torres, L | 1 |
| Bermúdez, V | 1 |
| Longardner, K | 1 |
| Wright, BA | 1 |
| Alakkas, A | 1 |
| You, H | 1 |
| Xu, R | 1 |
| Liu, L | 1 |
| Nahab, FB | 2 |
| Kurhan, F | 1 |
| Akın, M | 1 |
| Horn, S | 1 |
| Richardson, H | 1 |
| Xie, SX | 1 |
| Weintraub, D | 3 |
| Dahodwala, N | 1 |
| Morelhão, PK | 1 |
| Dokkedal-Silva, V | 1 |
| Galduróz, JCF | 1 |
| Tufik, S | 1 |
| Andersen, ML | 1 |
| Mansuri, Z | 1 |
| Patel, K | 1 |
| Desai, R | 1 |
| Zafar, MK | 1 |
| Jain, S | 1 |
| Kyle, K | 2 |
| Bronstein, JM | 2 |
| Ballard, CG | 2 |
| Kreitzman, DL | 2 |
| Isaacson, S | 4 |
| Liu, IY | 1 |
| Norton, JC | 6 |
| Demos, G | 2 |
| Fernandez, HH | 2 |
| Ilic, TV | 2 |
| Azulay, JP | 2 |
| Ferreira, JJ | 3 |
| Abler, V | 3 |
| Stankovic, S | 5 |
| Coate, B | 5 |
| Norton, J | 2 |
| DeKarske, D | 1 |
| Alva, G | 3 |
| Aldred, JL | 1 |
| Cantillon, M | 1 |
| Jacobi, L | 1 |
| Nunez, R | 1 |
| Cummings, JL | 2 |
| Devanand, DP | 2 |
| Stahl, SM | 4 |
| Christensen, LFB | 1 |
| Alijanvand, SH | 1 |
| Burdukiewicz, M | 1 |
| Herbst, FA | 1 |
| Kjeldal, H | 1 |
| Dueholm, MS | 1 |
| Otzen, DE | 1 |
| Tariot, PN | 1 |
| Soto-Martin, ME | 1 |
| Ballard, C | 6 |
| Erten-Lyons, D | 1 |
| Sultzer, DL | 1 |
| McEvoy, B | 1 |
| Youakim, JM | 1 |
| Foff, EP | 1 |
| Ali, F | 1 |
| An, H | 1 |
| Kumari, N | 2 |
| Agrawal, S | 2 |
| Luthra, PM | 2 |
| Bozymski, KM | 1 |
| Lowe, DK | 1 |
| Pasternak, KM | 1 |
| Gatesman, TL | 1 |
| Crouse, EL | 1 |
| Wilby, KJ | 1 |
| Johnson, EG | 1 |
| Johnson, HE | 1 |
| Ensom, MHH | 1 |
| Mathis, MV | 1 |
| Muoio, BM | 1 |
| Andreason, P | 1 |
| Avila, AM | 1 |
| Farchione, T | 1 |
| Atrakchi, A | 1 |
| Temple, RJ | 1 |
| Cozac, VV | 1 |
| Hermanowicz, N | 3 |
| Espay, AJ | 2 |
| Patel, A | 1 |
| Madrid, KC | 1 |
| Kremens, D | 2 |
| Kenney, J | 1 |
| Arquette, S | 1 |
| Tereso, G | 1 |
| Lopes, M | 1 |
| Farnum, C | 1 |
| Yuan, M | 1 |
| Sperry, L | 1 |
| Malhado-Chang, N | 1 |
| Duffy, A | 1 |
| Wheelock, V | 1 |
| Farias, S | 1 |
| O'Connor, K | 1 |
| Olichney, J | 1 |
| Shahlaie, K | 1 |
| Zhang, L | 1 |
| Fredericks, D | 2 |
| Atchison, C | 1 |
| Schoenhaus, R | 1 |
| Pill, MW | 1 |
| Velayudhan, L | 1 |
| Ffytche, D | 1 |
| Aarsland, D | 1 |
| Kianirad, Y | 1 |
| Simuni, T | 2 |
| Sahli, ZT | 1 |
| Tarazi, FI | 1 |
| Citrome, L | 2 |
| Chi-Burris, K | 2 |
| Panchal, SC | 1 |
| Ondo, WG | 1 |
| Friedman, JH | 4 |
| Kumari, R | 1 |
| Sharma, D | 1 |
| Webster, P | 1 |
| Schubmehl, S | 1 |
| Sussman, J | 1 |
| Moreno, GM | 1 |
| Gandhi, R | 1 |
| Lessig, SL | 1 |
| Wright, B | 1 |
| Litvan, I | 1 |
| Cummings, J | 2 |
| Tariot, P | 1 |
| Owen, R | 1 |
| Foff, E | 1 |
| Youakim, J | 1 |
| Guskey, MT | 1 |
| Vizcarra, JA | 1 |
| Factor, SA | 1 |
| Lang, AE | 1 |
| Larsen, NJ | 1 |
| Andersson, C | 1 |
| Black, KJ | 1 |
| Nasrallah, H | 1 |
| Stacy, M | 1 |
| Adler, CH | 1 |
| Cooney, JW | 1 |
| Menza, MA | 1 |
| Meyer, JM | 1 |
| Patkar, AA | 1 |
| Morrissette, DA | 1 |
| de la Cruz, J | 1 |
| Canal, C | 1 |
| Fragniere, AMC | 1 |
| Stott, SRW | 1 |
| Fazal, SV | 1 |
| Andreasen, M | 1 |
| Scott, K | 1 |
| Barker, RA | 1 |
| Sellers, J | 1 |
| Darby, RR | 1 |
| Farooque, A | 1 |
| Claassen, DO | 1 |
| Mohanty, D | 1 |
| Sarai, S | 1 |
| Naik, S | 1 |
| Lippmann, S | 1 |
| Mills, R | 3 |
| Williams, H | 4 |
| Corbett, A | 2 |
| Dhall, R | 1 |
| Fox, SH | 1 |
| Kingwell, K | 1 |
| Meltzer, HY | 2 |
| Roth, BL | 2 |
| Hacksell, U | 1 |
| Burstein, ES | 1 |
| McFarland, K | 2 |
| Mills, RG | 1 |
| Rascol, O | 1 |
| Burn, DJ | 2 |
| Hunter, NS | 1 |
| Anderson, KC | 1 |
| Cox, A | 1 |
| Howland, RH | 1 |
| Traynor, K | 1 |
| Markham, A | 1 |
| Xue, Y | 1 |
| Yang, YT | 1 |
| Liu, HY | 1 |
| Chen, WF | 1 |
| Chen, AQ | 1 |
| Sheng, Q | 1 |
| Chen, XY | 1 |
| Wang, Y | 1 |
| Chen, H | 1 |
| Liu, HX | 1 |
| Pang, YY | 1 |
| Chen, L | 1 |
| Chendo, I | 1 |
| Majlath, Z | 1 |
| Obal, I | 1 |
| Vecsei, L | 1 |
| Samudra, N | 1 |
| Patel, N | 1 |
| Womack, KB | 1 |
| Khemani, P | 1 |
| Chitnis, S | 1 |
| Abbas, A | 1 |
| Azam, F | 1 |
| Alkskas, IA | 1 |
| Ahmed, MA | 1 |
| Revell, S | 1 |
| Johnson, A | 1 |
| Bahr, D | 1 |
| Docherty, MJ | 1 |
| Guerreiro, TM | 1 |
| Nishikawa, DR | 1 |
| Ferreira, LC | 1 |
| Melo, HA | 1 |
| Prado, RC | 1 |
| Price, DL | 1 |
| Bonhaus, DW | 1 |
| Pilleri, M | 1 |
| Koutsikos, K | 1 |
| Antonini, A | 1 |
| Lieberman, A | 1 |
| Krishnamurthi, N | 1 |
| Ng, LK | 1 |
| Chase, TN | 1 |
| Colburn, RW | 1 |
| Kopin, IJ | 1 |
| Van Wieringen, A | 1 |
| Jeffery, DJ | 1 |
| Brown, DM | 1 |
| Langley, PF | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| An Open-label, 8-Week Study of Safety and Efficacy of Pimavanserin Treatment in Adults With Parkinson's Disease and Depression[NCT03482882] | Phase 2 | 47 participants (Actual) | Interventional | 2018-03-09 | Completed | ||
| A Double-blind, Placebo-controlled, Relapse Prevention Study of Pimavanserin for the Treatment of Hallucinations and Delusions Associated With Dementia-related Psychosis[NCT03325556] | Phase 3 | 392 participants (Actual) | Interventional | 2017-09-27 | Completed | ||
| A Multi-Center, Open-Label Extension Study to Examine the Safety and Tolerability of ACP-103 in the Treatment of Psychosis in Parkinson's Disease[NCT00550238] | Phase 3 | 459 participants (Actual) | Interventional | 2007-07-31 | Completed | ||
| A Multi-Center, Placebo-Controlled, Double-Blind Trial to Examine the Safety and Efficacy of Pimavanserin in the Treatment of Psychosis in Parkinson's Disease[NCT01174004] | Phase 3 | 199 participants (Actual) | Interventional | 2010-07-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The CGI-I is a clinician-rated 7-point scale to rate the improvement in the patient's depression at the time of assessment relative baseline. The CGI-I ranges from 1 (very much improved) to 7 (very much worse) (NCT03482882)
Timeframe: At Week 8
| Intervention | score on a scale (Mean) |
|---|---|
| Pimavanserin Full Analysis Set | 2.0 |
"The HAMD-17 is a multiple-item questionnaire to assess the severity of depression, including items of mood, feelings of guilt, suicide ideation, insomnia, agitation or retardation, anxiety, weight loss, and somatic symptoms. Each of the 17 items is scored on a 3- or 5-point scale (depending on the item). The minimum total score is 0; the maximum total score is 52. A higher total score signifies more severe Depression.~Response was defined as ≥50% reduction from baseline in HAMD-17 total score. Patients without Week-8 score were counted as nonresponders." (NCT03482882)
Timeframe: From baseline to Week 8
| Intervention | Participants (Count of Participants) |
|---|---|
| Pimavanserin Full Analysis Set | 27 |
The CGI-S is a clinician-rated 7-point scale to rate the severity of the patient's depression at the time of assessment. The CGI-S ranges from 1 (normal) to 7 (patient is among the most severely ill). (NCT03482882)
Timeframe: From baseline to Week 8
| Intervention | score on a scale (Mean) | |
|---|---|---|
| Baseline CGI-S | 8 Week CGI-S CFB | |
| Pimavanserin Full Analysis Set | 4.1 | -1.8 |
The HAMD-17 is a multiple-item questionnaire to assess the severity of depression, including items of mood, feelings of guilt, suicide ideation, insomnia, agitation or retardation, anxiety, weight loss, and somatic symptoms. Each of the 17 items is scored on a 3- or 5-point scale (depending on the item). The minimum total score is 0; the maximum total score is 52. A higher total score signifies more severe depression. (NCT03482882)
Timeframe: 2, 4, and 6 weeks from baseline
| Intervention | score on a scale (Mean) | |||
|---|---|---|---|---|
| Baseline HAMD-17 total score | Week 2 HAMD-17 total score CFB | Week 4 HAMD-17 total score CFB | Week 6 HAMD-17 total score CFB | |
| Pimavanserin Full Analysis Set | 19.2 | -7.5 | -9.7 | -9.6 |
The SCOPA-NS subscale addresses problems in nighttime sleep and consists of 5 items (sleep initiation, sleep fragmentation, sleep efficiency, sleep duration, early wakening). Each item has 4 response options (ranging from 0=not at all to 3=a lot). The SCOPA-NS score ranges from 0 to 15, with a higher score indicating more severe nighttime sleep problems. (NCT03482882)
Timeframe: From baseline to Week 8
| Intervention | score on a scale (Mean) | |
|---|---|---|
| Baseline SCOPA-NS | Week 8 SCOPA-NS CFB | |
| Pimavanserin Full Analysis Set | 6.1 | -2.1 |
The SCOPA-DS subscale addresses problems in daytime sleepiness and consists of 6 items (falling asleep unexpectedly, falling asleep peacefully, falling asleep watching TV/reading, falling asleep while talking to someone, having difficulty staying awake, whether falling asleep in the daytime is considered a Problem). Each item has 4 response options (from 0=never to 3=often). The SCOPA-DS subscale score ranges from 0 to 18, with a higher score indicating more severe DS problems. (NCT03482882)
Timeframe: From baseline to Week 8
| Intervention | score on a scale (Mean) | |
|---|---|---|
| Baseline SCOPA-DS | 8 Week SCOPA-DS CFB | |
| Pimavanserin Full Analysis Set | 5.2 | -2.2 |
"The EQ-5D-5L is a standardized measure of health status. The questionnaire consists of 2 components: the EQ-5D-5L descriptive system and the EQ-5D-5L Visual Analogue scale (EQ-5D-5L VAS). The descriptive system consists of 5 dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression). Each dimension has 5 levels (from 1=no problem to 5=extreme Problems). The digits for the 5 dimensions are combined into a 5-digit code that describes the patient's health state, which is then converted into a single summary index value. Health state index scores generally range from less than 0 (where 0 is the value of a health state equivalent to dead; negative values representing values as worse than dead) to 1 (the value of full health), with higher scores indicating higher health utility.~The EQ-5D-5L VAS records the patient's health on a vertical visual analogue scale, ranging from 100 (=the best health you can imagine) to 0 (=the worst health you can imagine)." (NCT03482882)
Timeframe: From baseline to Week 8
| Intervention | score on a scale (Mean) | |||
|---|---|---|---|---|
| Baseline EQ-5D-5L index score | 8 Week EQ-5D-5L index score CFB | Baseline EQ-5D-5L VAS | 8 Week EQ-5D-5L VAS CFB | |
| Pimavanserin Full Analysis Set | 0.6750 | 0.0712 | 63.9 | 6.7 |
The HAMD-17 is a multiple-item questionnaire to assess the severity of depression, including items of mood, feelings of guilt, suicide ideation, insomnia, agitation or retardation, anxiety, weight loss, and somatic symptoms. Each of the 17 items is scored on a 3- or 5-point scale (depending on the item). The minimum total score is 0; the maximum total score is 52. A higher total score signifies more severe depression. (NCT03482882)
Timeframe: From baseline to Week 8
| Intervention | score on a scale (Mean) | |
|---|---|---|
| Baseline HAMD-17 total score | Week 8 HAMD-17 total score | |
| Pimavanserin Full Analysis Set | 19.2 | 8.1 |
The endpoint of time from randomization to discontinuation from the DB period for any reason (other than termination of the study by the sponsor) was compared between treatment groups using a Cox regression model. The treatment effect was measured by the HR. (NCT03325556)
Timeframe: From randomization in the DB period through 26 weeks
| Intervention | days (Median) |
|---|---|
| Pimavanserin Double-Blind Period | NA |
| Placebo Double-Blind Period | NA |
"The time from randomization to relapse in the DB period was compared between treatment groups using a Cox regression model. The treatment effect was measured by the hazard ratio (HR).~Relapse was defined as (1) ≥30% increase in SAPS-H+D total score from DB baseline (BL) and CGI-I score ≥6 relative to DB BL, (2) treatment with antipsychotic for dementia-related delusions/hallucinations, (3) treatment/study discontinuation due to lack of efficacy, and/or (4) hospitalization for worsening dementia-related psychosis.~SAPS-H+D is a 20-item scale; the total score is the sum of the 20 item scores (range 0-100); higher scores denote more severe symptoms. CGI-I is a clinician-rated 7-point scale to rate improvement in hallucinations/delusions relative to BL (range 1-7); higher scores denote less improvement or worsening.~A pre-specified IA was conducted after accrual of 40 adjudicated relapse events. The prespecified stopping criterion was met; the study was stopped for efficacy." (NCT03325556)
Timeframe: From randomization in the DB period through 26 weeks
| Intervention | days (Median) |
|---|---|
| Pimavanserin Double-Blind Period | NA |
| Placebo Double-Blind Period | NA |
Number (%) of patients with drug-related treatment-emergent AEs (i.e. AEs reported by the Investigator as possibly, probably, or highly probably related to study drug) (NCT00550238)
Timeframe: From first to last study drug dose plus 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Pimavanserin | 180 |
"Antipsychotic Efficacy was defined as a decrease in the severity and/or frequency of hallucinations and/or delusions. This is measured as the change from baseline (Day 1) to Day 43 in the Scale for the Assessment of Positive Symptoms 9-item sum score for Parkinson's Disease (SAPS-PD). The possible total score is 0 to 45 and a negative change in score indicates improvement.~Analysis Method: Mixed Model Repeated Measures (MMRM)" (NCT01174004)
Timeframe: Each study visit (i.e. Days 1, 15, 29 and 43)
| Intervention | Score on the SAPS-PD scale (Least Squares Mean) | |
|---|---|---|
| Change from Baseline | Difference of Least Squares Mean versus Placebo | |
| Pimavanserin 40 mg | -5.79 | -3.06 |
| Placebo | -2.73 | NA |
"Motor symptoms were measured using the change from baseline to Day 43 in the combined score of the Unified Parkinson's Disease Rating Scale (UPDRS) Part II (Activities of Daily Living) and Part III (Motor Examination). The possible total score is 0 to 160 and a negative change in score indicates improvement.~Analysis Method: Analysis of Covariance (ANCOVA). The UPDRS Parts II+III score was analyzed by constructing 2-sided 95% confidence intervals (CIs) on the difference between the pimavanserin dose group and placebo mean change from baseline. Non-inferiority was concluded if the upper limit of the CI was less than or equal to 5." (NCT01174004)
Timeframe: Study Days 1 and 43
| Intervention | Score on the UPDRS-II+III (Least Squares Mean) | |
|---|---|---|
| Change from Baseline | Difference of Least Squares Mean versus Placebo | |
| Pimavanserin 40 mg | -1.40 | 0.29 |
| Placebo | -1.69 | NA |
28 reviews available for urea and Parkinson Disease
| Article | Year |
|---|---|
Unmet needs in the diagnosis and treatment of Parkinson's disease psychosis and dementia-related psychosis.
Topics: Alzheimer Disease; Antipsychotic Agents; Humans; Parkinson Disease; Piperidines; Psychotic Disorders | 2023 |
Psychosis in Parkinson's Disease: Looking Beyond Dopaminergic Treatments.
Topics: Antipsychotic Agents; Dopamine; Hallucinations; Humans; Illusions; Parkinson Disease; Psychotic Diso | 2022 |
A New Hope in Alzheimer's Disease Psychosis: Pimavanserin.
Topics: Alzheimer Disease; Antipsychotic Agents; Humans; Parkinson Disease; Psychotic Disorders; United Stat | 2023 |
Treatment of psychosis in Parkinson's disease and dementia with Lewy Bodies: A review.
Topics: Antipsychotic Agents; Humans; Lewy Body Disease; Parkinson Disease; Piperidines; Psychotic Disorders | 2020 |
Dementia-related psychosis and the potential role for pimavanserin.
Topics: Dementia; Hallucinations; Humans; Parkinson Disease; Piperidines; Psychotic Disorders; Urea | 2022 |
Pimavanserin: A Novel Antipsychotic for Parkinson's Disease Psychosis.
Topics: Antiparkinson Agents; Antipsychotic Agents; Delusions; Hallucinations; Humans; Parkinson Disease; Pi | 2017 |
Evidence-Based Review of Pharmacotherapy Used for Parkinson's Disease Psychosis.
Topics: Antipsychotic Agents; Benzodiazepines; Clozapine; Evidence-Based Medicine; Humans; Olanzapine; Parki | 2017 |
The US Food and Drug Administration's Perspective on the New Antipsychotic Pimavanserin.
Topics: Antipsychotic Agents; Delusions; Hallucinations; Humans; Parkinson Disease; Piperidines; United Stat | 2017 |
The Emerging Role of Pimavanserin in the Management of Parkinson's Disease Psychosis.
Topics: Animals; Humans; Parkinson Disease; Piperidines; Psychotic Disorders; Quality of Life; Urea | 2017 |
Parkinson's disease and Parkinson's disease psychosis: a perspective on the challenges, treatments, and economic burden.
Topics: Antipsychotic Agents; Cost of Illness; Health Care Costs; Humans; Parkinson Disease; Piperidines; Ps | 2017 |
New Therapeutic Strategies for Lewy Body Dementias.
Topics: alpha-Synuclein; Cholinesterase Inhibitors; Disease Management; Genetic Therapy; Humans; Lewy Body D | 2017 |
Pimavanserin, a novel antipsychotic for management of Parkinson's disease psychosis.
Topics: Antipsychotic Agents; Delusions; Drug Inverse Agonism; Hallucinations; Humans; Parkinson Disease; Pi | 2017 |
Pimavanserin: novel pharmacotherapy for Parkinson's disease psychosis.
Topics: Animals; Antipsychotic Agents; Delusions; Hallucinations; Humans; Parkinson Disease; Piperidines; Ps | 2018 |
Pimavanserin for the treatment of Parkinson's disease psychosis: number needed to treat, number needed to harm, and likelihood to be helped or harmed.
Topics: Clinical Trials as Topic; Humans; Numbers Needed To Treat; Parkinson Disease; Piperidines; Psychotic | 2018 |
Delusional misidentification in Parkinson's disease: report of two cases and a review.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Delusions; Female; Humans; Male; Parkinson Disease; P | 2018 |
Treating Hallucinations and Delusions Associated With Parkinson's Disease Psychosis.
Topics: Antipsychotic Agents; Delusions; Hallucinations; Humans; Parkinson Disease; Piperidines; Psychotic D | 2018 |
Pharmacological interventions for psychosis in Parkinson's disease patients.
Topics: Antipsychotic Agents; Clozapine; Dopamine; Humans; Parkinson Disease; Piperidines; Psychotic Disorde | 2018 |
Pimavanserin: Potential Treatment For Dementia-Related Psychosis.
Topics: Alzheimer Disease; Clinical Trials as Topic; Dementia; Humans; Mental Status and Dementia Tests; Par | 2018 |
Guidance for switching from off-label antipsychotics to pimavanserin for Parkinson's disease psychosis: an expert consensus.
Topics: Antiparkinson Agents; Antipsychotic Agents; Consensus; Drug Substitution; Humans; Off-Label Use; Par | 2018 |
Pimavanserin for the treatment of Parkinson's disease psychosis.
Topics: Animals; Antiparkinson Agents; Humans; Parkinson Disease; Piperidines; Psychotic Disorders; Serotoni | 2013 |
Lorcaserin and pimavanserin: emerging selectivity of serotonin receptor subtype-targeted drugs.
Topics: Benzazepines; Diabetes Mellitus, Type 2; Heart Valve Diseases; Humans; Molecular Structure; Obesity; | 2013 |
On the discovery and development of pimavanserin: a novel drug candidate for Parkinson's psychosis.
Topics: Drug Discovery; Humans; Parkinson Disease; Piperidines; Psychotic Disorders; Urea | 2014 |
Pimavanserin.
Topics: Animals; Clinical Trials as Topic; Humans; Parkinson Disease; Piperidines; Psychotic Disorders; Sero | 2015 |
Pimavanserin: First Global Approval.
Topics: Antipsychotic Agents; Delusions; Drug Approval; Drug Discovery; Drug Evaluation, Preclinical; Halluc | 2016 |
Pimavanserin for the treatment of Parkinson's disease psychosis.
Topics: Antipsychotic Agents; Humans; Parkinson Disease; Piperidines; Psychotic Disorders; Schizophrenia; Se | 2016 |
Psychosis in Parkinson Disease: A Review of Etiology, Phenomenology, and Management.
Topics: Antipsychotic Agents; Cholinesterase Inhibitors; Clozapine; Humans; Molecular Targeted Therapy; Neur | 2016 |
Pimavanserin tartrate: a 5-HT2A inverse agonist with potential for treating various neuropsychiatric disorders.
Topics: Clinical Trials as Topic; Humans; Molecular Structure; Parkinson Disease; Piperidines; Schizophrenia | 2008 |
Parkinson's disease dementia.
Topics: Cholinesterase Inhibitors; Clinical Trials as Topic; Dementia; Diagnosis, Differential; Humans; Park | 2010 |
8 trials available for urea and Parkinson Disease
| Article | Year |
|---|---|
Blinded SAPS-PD Assessment After 10 Weeks of Pimavanserin Treatment for Parkinson's Disease Psychosis.
Topics: Aged; Aged, 80 and over; Double-Blind Method; Female; Humans; Male; Middle Aged; Outcome Assessment, | 2020 |
An Open-Label, 8-Week Study of Safety and Efficacy of Pimavanserin Treatment in Adults with Parkinson's Disease and Depression.
Topics: Aged; Depression; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Outcome Assessment, | 2020 |
Efficacy results of pimavanserin from a multi-center, open-label extension study in Parkinson's disease psychosis patients.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Double-Blind Method; Female; Humans; Male; Middle Age | 2021 |
Trial of Pimavanserin in Dementia-Related Psychosis.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Dementia; Double-Blind Method; Female; Hallucinations | 2021 |
Pimavanserin for Parkinson's Disease psychosis: Effects stratified by baseline cognition and use of cognitive-enhancing medications.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Cognition Disorders; Double-Blind Method; Female; Hum | 2018 |
Pimavanserin for patients with Parkinson's disease psychosis: a randomised, placebo-controlled phase 3 trial.
Topics: Aged; Analysis of Variance; Antiparkinson Agents; Antipsychotic Agents; Double-Blind Method; Female; | 2014 |
Impact of Current Antipsychotic Medications on Comparative Mortality and Adverse Events in People With Parkinson Disease Psychosis.
Topics: Accidental Falls; Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Antipsychotic Agents; Drug T | 2015 |
Pimavanserin, a serotonin(2A) receptor inverse agonist, for the treatment of parkinson's disease psychosis.
Topics: Aged; Analysis of Variance; Double-Blind Method; Female; Follow-Up Studies; Humans; Male; Motor Acti | 2010 |
47 other studies available for urea and Parkinson Disease
| Article | Year |
|---|---|
The Compound ATH434 Prevents Alpha-Synuclein Toxicity in a Murine Model of Multiple System Atrophy.
Topics: alpha-Synuclein; Animals; Disease Models, Animal; Humans; Iron; Mice; Mice, Transgenic; Multiple Sys | 2022 |
Reader Response: Risk of Hospitalization and Death Associated With Pimavanserin Use in Older Adults With Parkinson Disease.
Topics: Aged; Hospitalization; Humans; Parkinson Disease; Piperidines; Urea | 2022 |
Author Response: Risk of Hospitalization and Death Associated With Pimavanserin Use in Older Adults With Parkinson Disease.
Topics: Aged; Hospitalization; Humans; Parkinson Disease; Piperidines; Urea | 2022 |
Improving the treatment of Parkinson's disease: Structure-based development of novel 5-HT
Topics: Aged; Antipsychotic Agents; Humans; Parkinson Disease; Psychotic Disorders; Receptor, Serotonin, 5-H | 2022 |
Aggregation of a Parkinson's Disease-Related Peptide: When Does Urea Weaken Hydrophobic Interactions?
Topics: Humans; Hydrophobic and Hydrophilic Interactions; Parkinson Disease; Peptides; Protein Aggregates; U | 2022 |
Mortality Among Parkinson's Disease Patients Treated With Pimavanserin or Atypical Antipsychotics: An Observational Study in Medicare Beneficiaries.
Topics: Aged; Antipsychotic Agents; Cohort Studies; Female; Humans; Male; Medicare; Parkinson Disease; Piper | 2022 |
The Safety of Pimavanserin for Parkinson's Disease and Efforts to Reduce Antipsychotics for People With Dementia.
Topics: Antipsychotic Agents; Dementia; Humans; Parkinson Disease; Piperidines; Psychotic Disorders; Urea | 2022 |
Assessing the risks of treatment in Parkinson disease psychosis: An in-depth analysis.
Topics: Aged; Antipsychotic Agents; Dementia; Humans; Levodopa; Parkinson Disease; Prospective Studies; Psyc | 2023 |
Pimavanserin versus quetiapine for the treatment of psychosis in Parkinson's disease and dementia with Lewy bodies.
Topics: Adult; Aged; Aged, 80 and over; Antipsychotic Agents; Cohort Studies; Female; Humans; Lewy Body Dise | 2019 |
The use of Pimavanserin in the treatment of Parkinson's disease: a consideration of its effects on sleep.
Topics: Cross-Sectional Studies; Genotype; Humans; Parkinson Disease; Piperidines; Psychotic Disorders; Slee | 2020 |
Pimavanserin: A 2019 Clarification on the FDA Update.
Topics: Humans; Parkinson Disease; Piperidines; Psychotic Disorders; Urea | 2019 |
Long-term evaluation of open-label pimavanserin safety and tolerability in Parkinson's disease psychosis.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Female; Hallucinations; Humans; Male; Middle Aged; Pa | 2020 |
Treatment of Psychosis in Parkinson's disease and sudden death.
Topics: Antipsychotic Agents; Death, Sudden; Humans; Parkinson Disease; Piperidines; Psychotic Disorders; Ur | 2020 |
Identification of amyloidogenic proteins in the microbiomes of a rat Parkinson's disease model and wild-type rats.
Topics: alpha-Synuclein; Amino Acid Sequence; Amyloid; Amyloidogenic Proteins; Animals; Bacterial Proteins; | 2021 |
Pimavanserin: A Friend or Foe in Parkinson Disease Psychosis.
Topics: Aged; Hospitalization; Humans; Parkinson Disease; Piperidines; Psychotic Disorders; Urea | 2021 |
Risk of Hospitalization and Death Associated With Pimavanserin Use in Older Adults With Parkinson Disease.
Topics: Aged; Hospitalization; Humans; Medicare; Parkinson Disease; Piperidines; Psychotic Disorders; Retros | 2021 |
Pharmacological assessments of potent A
Topics: Adenosine A2 Receptor Antagonists; Adenosine-5'-(N-ethylcarboxamide); Animals; Antiparkinson Agents; | 2017 |
[Modern approaches to treatment of psychosis in Parkinson's disease].
Topics: Antiparkinson Agents; Antipsychotic Agents; Clozapine; Humans; Parkinson Disease; Piperidines; Psych | 2016 |
Atypical antipsychotic therapy in Parkinson's disease psychosis: A retrospective study.
Topics: Aged; Antipsychotic Agents; Benzodiazepines; Drug-Related Side Effects and Adverse Reactions; Female | 2017 |
Neuroprotective effect of IDPU (1-(7-imino-3-propyl-2,3-dihydrothiazolo [4,5-d]pyrimidin-6(7H)-yl)urea) in 6-OHDA induced rodent model of hemiparkinson's disease.
Topics: Animals; Antiparkinson Agents; Behavior, Animal; Depression; Disease Models, Animal; Male; Neuroprot | 2018 |
Pimavanserin evaluated by the FDA.
Topics: Antipsychotic Agents; Delusions; Drug Evaluation; Hallucinations; Humans; Parkinson Disease; Piperid | 2018 |
Difficult choices in treating Parkinson's disease psychosis.
Topics: Antipsychotic Agents; Drug Approval; Humans; Off-Label Use; Parkinson Disease; Piperidines; Psychoti | 2018 |
Perspective on Pimavanserin and the SAPS-PD: Novel Scale Development as a Means to FDA Approval.
Topics: Antipsychotic Agents; Clinical Trials as Topic; Drug Approval; Humans; Outcome Assessment, Health Ca | 2018 |
Mortality in patients with Parkinson disease psychosis receiving pimavanserin and quetiapine.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Female; Humans; Male; Middle Aged; Parkinson Disease; | 2018 |
Psychiatric commentary addressing the article titled "Guidance for switching from off-label antipsychotics to pimavanserin for Parkinson's disease psychosis: an expert consensus".
Topics: Antipsychotic Agents; Consensus; Humans; Neurodegenerative Diseases; Off-Label Use; Parkinson Diseas | 2018 |
Neurological commentary addressing the article titled "Guidance for switching from off-label antipsychotics to pimavanserin for Parkinson's disease psychosis: an expert consensus".
Topics: Antipsychotic Agents; Consensus; Humans; Off-Label Use; Parkinson Disease; Piperidines; Psychotic Di | 2018 |
Can pimavanserin help patients with Parkinson disease psychosis?
Topics: Antipsychotic Agents; Humans; Parkinson Disease; Piperidines; Psychotic Disorders; Serotonin 5-HT2 R | 2019 |
Hyperosmotic stress induces cell-dependent aggregation of α-synuclein.
Topics: alpha-Synuclein; Animals; Benzothiazoles; Blotting, Western; Cell Death; Cell Line; Cell Survival; E | 2019 |
Pimavanserin for Psychosis in Parkinson's Disease-Related Disorders: A Retrospective Chart Review.
Topics: Aged; Antiparkinson Agents; Antipsychotic Agents; Female; Humans; Male; Parkinson Disease; Piperidin | 2019 |
Pimavanserin for Parkinson Disease Psychosis.
Topics: Antiparkinson Agents; Antipsychotic Agents; Humans; Parkinson Disease; Piperidines; Psychotic Disord | 2019 |
Pimavanserin as treatment for Parkinson's disease psychosis.
Topics: Antiparkinson Agents; Antipsychotic Agents; Female; Humans; Male; Parkinson Disease; Piperidines; Ps | 2014 |
Parkinson disease: Pimavanserin could be useful for treating psychosis in Parkinson disease.
Topics: Antiparkinson Agents; Antipsychotic Agents; Female; Humans; Male; Parkinson Disease; Piperidines; Ps | 2013 |
Pimavanserin: An Inverse Agonist Antipsychotic Drug.
Topics: Female; Humans; Male; Parkinson Disease; Piperidines; Psychotic Disorders; Serotonin 5-HT2 Receptor | 2016 |
Pimavanserin (Nuplazid) for Parkinson's disease psychosis.
Topics: Antiparkinson Agents; Antipsychotic Agents; Drug Administration Schedule; Drug Costs; Drug Interacti | 2016 |
Pimavanserin approved for Parkinson's-related hallucinations, delusions.
Topics: Antiparkinson Agents; Delusions; Drug Approval; Drug Labeling; Hallucinations; Humans; Parkinson Dis | 2016 |
Orexin-A increases the activity of globus pallidus neurons in both normal and parkinsonian rats.
Topics: Action Potentials; Animals; Benzoxazoles; Globus Pallidus; Haloperidol; Male; Naphthyridines; Neuron | 2016 |
Mechanism of action of pimavanserin in Parkinson's disease psychosis: targeting serotonin 5HT2A and 5HT2C receptors.
Topics: Humans; Parkinson Disease; Piperidines; Psychotic Disorders; Receptor, Serotonin, 5-HT2A; Receptor, | 2016 |
Parkinson's disease psychosis as a serotonin-dopamine imbalance syndrome.
Topics: Antiparkinson Agents; Antipsychotic Agents; Brain; Dopamine; Humans; Levodopa; Lewy Bodies; Parkinso | 2016 |
Treatment Possibilities for Psychosis in Parkinson's Disease with An Emphasis on the Newly Approved Drug: Pimavanserin.
Topics: Animals; Humans; Parkinson Disease; Piperidines; Psychotic Disorders; Receptor, Serotonin, 5-HT2A; S | 2017 |
Synthesis of some urea and thiourea derivatives of 3-phenyl/ethyl-2-thioxo-2,3-dihydrothiazolo[4,5-d]pyrimidine and their antagonistic effects on haloperidol-induced catalepsy and oxidative stress in mice.
Topics: Animals; Anti-Dyskinesia Agents; Antiparkinson Agents; Brain; Catalepsy; Glutathione; Glutathione Pe | 2009 |
Restless legs syndrome in Parkinson's disease: clinical characteristics and biochemical correlations.
Topics: Aged; Female; Ferritins; Hemoglobins; Humans; Iron; Male; Middle Aged; Parkinson Disease; Restless L | 2010 |
Pimavanserin, a 5-HT2A inverse agonist, reverses psychosis-like behaviors in a rodent model of Parkinson's disease.
Topics: Amphetamine; Amphetamines; Animals; Antipsychotic Agents; Behavior, Animal; Central Nervous System S | 2011 |
Is there room for new non-dopaminergic treatments in Parkinson's disease?
Topics: Antiparkinson Agents; Droxidopa; Humans; Parkinson Disease; Piperidines; Urea | 2013 |
Is there room for non-dopaminergic treatment in Parkinson disease?
Topics: Antiparkinson Agents; Droxidopa; Humans; Parkinson Disease; Piperidines; Treatment Outcome; Urea | 2013 |
L-dopa in Parkinsonism. A possible mechanism of action.
Topics: Amines; Animals; Basal Ganglia; Brain; Carbon Isotopes; Cerebral Cortex; Corpus Striatum; Dihydroxyp | 1972 |
Bensarazid with L-dopa in the treatment of parkinson's disease.
Topics: Adult; Aged; Benserazide; Dihydroxyphenylalanine; Drug Therapy, Combination; Female; Humans; Hydrazi | 1974 |
The metabolism and distribution of benapryzine.
Topics: Administration, Oral; Animals; Autoradiography; Benzilates; Bile; Brain; Carbon Radioisotopes; Chrom | 1971 |